Bayer starts phase II/III study with vericiguat in children with heart failure
Bayer and its development partner MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA) announced that the first patient has been enrolled in the Phase II/III VALOR trial. VALOR will investigate the efficacy, afety, and pharmacokinetics of vericiguat (Verquvo) in pediatric patients aged greater than 28 days to 18 years with heart failure due to left ventricular systolic […]
Recent Comments